Lakewood-Amedex Biotherapeutics Inc. Net Fee Amt
Lakewood-Amedex Biotherapeutics Inc. (LABT) had Net Fee Amt of $1.22 thousand as of 2026-09-16, per its S-1 filed 2026-09-18.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-18
- 2026-09-16: Net Fee Amt $1.22K.
- 2026-05-01: Net Fee Amt $4.06K.
| Period end | Net Fee Amt |
|---|---|
| 2026-09-16 | $1.22K S-1 · filed 2026-09-18 |
| 2026-05-01 | $4.06K S-1 · filed 2026-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B |